SCHOTT Pharma AG & Co KgaA (1SXP.DE) stock: key figures, P/E, revenue and dividend
Health Care · Germany · ISIN DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 957.00 m EUR | 986.00 m EUR |
| Gross profit | 322.00 m EUR | 332.00 m EUR |
| Operating income | 188.84 m EUR | 185.74 m EUR |
| EBIT | 189.00 m EUR | 0.00 EUR |
| Net income | 149.00 m EUR | 146.00 m EUR |
| Diluted EPS – continuing operations | 0.99 EUR | 0.97 EUR |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SCHOTT Pharma AG & Co KgaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
More stocks
- Athens International Airport SA (AIA.AT)
- Brookfield Infrastructure Corp (BIPC)
- Mazda Motor Corp (7261.T)
- 3SBio Inc (1530.HK)
- Dianthus Therapeutics, Inc. /DE/ (DNTH)
- Copperstone Resources AB (publ) (COPP B.ST)
- GDS Holdings Ltd (9698.HK)
- Doosan Pref Shs (000155.KS)
- Henan Pinggao Electric Co Ltd (600312.SS)
- Freshworks Inc. (FRSH)
- Mondi PLC (MNDI.L)
- UNITED COMMUNITY BANKS INC (UCB)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.